2023-01-25 09:52:50

Thousands of migraine sufferers could benefit from drug on NHS

Logo The Independent
The Independent
By Jane Kirby

Thousands of people who suffer from migraines could benefit from a drug that has been approved on the NHS.

The National Institute for Health and Care Excellence (Nice) said it was recommending eptinezumab (also called Vyepti) for preventing migraine in around 164,000 adults where at least three previous preventive treatments have failed.

The drug is taken in hospital every 12 weeks as an intravenous infusion and works to stave off migraines.

Nice said medical opinion suggests eptinezumab would be reserved for people with severe migraine attacks or who may be unable to take other jabs at home.

Continue read on independent.co.uk

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:12:00
The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine...

Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...

Logo Nasdaq
Business / FinanceBy Rtt News2023-01-23 13:22:13
(RTTNews) - Blueprint Medicines Corporation (BPMC) announced the FDA has accepted the company's supplemental new drug application for AYVAKIT for the...

Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first...

Logo EIN Presswire
HealthPress Release2023-01-24 10:58:20
Epidural Anesthesia Disposable Devices Epidural anesthesia offers analgesia or reduces pain rather than providing an anesthetic effect. BURLINGAME,...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and...

Logo PR Newswire
TechnologyPress Release2023-01-24 19:12:00
Pay as little as $0 for your prescriptions TROY, N.Y. and PHILADELPHIA, Jan. 24, 2023 /PRNewswire/ -- Health Insurance Solutions Inc. (HISI) and Levrx...

Logo CNBC
Business / FinanceBy Spencer Kimball2023-01-24 13:36:05
Key Points Anti-abortion physicians are suing to overturn the FDA's approval of mifepristone, which dates back more than two decades. Mifepristone used in...

Logo EIN Presswire
HealthPress Release2023-01-24 10:48:12
Childhood Absence Epilepsy Treatment Market Absence seizures (previously known as petit-mal) are commonly found in children than in adults with frequent...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
The aggregate German, Irish and Dutch market for erectile dysfunction (ED) market exceeds $175 million Aspargo plans to launch Sildenafil Spray in Germany,...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:09:00
VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:30:00
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone...

Logo PR Newswire
HealthPress Release2023-01-23 13:00:00
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:17:00
HAMILTON, BERMUDA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant...

Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS)...

Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
Data Represent Research and Development Work Being Conducted at Tonixs Infectious Disease R&D Center (RDC) in Frederick, Md. CHATHAM, N.J., Jan. 24, 2023...

Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...

Logo PR Newswire
HealthPress Release2023-01-24 13:05:00
ALTSTAETTEN, Switzerland, Jan. 24, 2023 /PRNewswire/ -- icotec ag, the leading medical device manufacturer of Carbon/PEEK spinal implants, announces the U.S....

Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 22:46:00
Verastem Oncology VSTM, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a...